DVAX - ダイナバックス・テクノロジ―ズ （Dynavax Technologies Corporation）DVAXのニュース
Dynavax to Present at the JMP Securities Life Sciences Conference 2023/05/08 20:15:00 PR Newswire
EMERYVILLE, Calif., May 8, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the JMP Securities Life…
Dynavax Technologies: The Covid Lifeline Expires 2023/05/03 19:17:55 Seeking Alpha
Dynavax Technologies reported Q1 earnings after hours on Tuesday. Its HEPLISAV-B franchise continues taking market share. Click for our thoughts on DVAX stock.
Dynavax Technologies (DVAX) Q1 2023 Earnings Call Transcript 2023/05/03 02:00:18 The Motley Fool
DVAX earnings call for the period ending March 31, 2023.
Dynavax Technologies Corporation (DVAX) Q1 2023 Earnings Call Transcript 2023/05/02 23:33:06 Seeking Alpha
Dynavax Technologies Corporation (NASDAQ:NASDAQ:DVAX) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ETCompany ParticipantsPaul Cox - VP of IR and Corporate CommunicationsRyan Spencer…
Dynavax misses on bottom line, but reaffirms 2023 guidance 2023/05/02 21:11:45 Seeking Alpha
Although its Q1 2023 bottom line results came in below expectations, Dynavax Technologies (DVAX) is trading flat in after-hours trading. Read more here.
Dynavax to Present at the JMP Securities Life Sciences Conference 2023/05/08 20:15:00 PR Newswire
EMERYVILLE, Calif., May 8, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the JMP Securities Life…
Dynavax Technologies: The Covid Lifeline Expires 2023/05/03 19:17:55 Seeking Alpha
Dynavax Technologies reported Q1 earnings after hours on Tuesday. Its HEPLISAV-B franchise continues taking market share. Click for our thoughts on DVAX stock.
Dynavax Technologies (DVAX) Q1 2023 Earnings Call Transcript 2023/05/03 02:00:18 The Motley Fool
DVAX earnings call for the period ending March 31, 2023.
Dynavax Technologies Corporation (DVAX) Q1 2023 Earnings Call Transcript 2023/05/02 23:33:06 Seeking Alpha
Dynavax Technologies Corporation (NASDAQ:NASDAQ:DVAX) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ETCompany ParticipantsPaul Cox - VP of IR and Corporate CommunicationsRyan Spencer…
Dynavax misses on bottom line, but reaffirms 2023 guidance 2023/05/02 21:11:45 Seeking Alpha
Although its Q1 2023 bottom line results came in below expectations, Dynavax Technologies (DVAX) is trading flat in after-hours trading. Read more here.
7 Biotech Stocks Sitting in the Sweet Spot 2023/03/24 10:30:57 InvestorPlace
Biotech stocks aren’t for everyone. They require some additional research and as an investor you have to be comfortable having product pipelines with a long pathway to market. Biotech companies can pour millions into research and development and have nothing to show with it. Biotech companies are on the leading edge of scientific innovation, and they bring in massive profits if they develop a drug that’s deemed to be safe and marketable. Small biotech companies that have potentially attractive drugs in their pipelines can draw the attention of larger pharmaceutical companies. That could lead to buyouts that could be extremely profitable for investors who get in on the ground floor. So, if you’ve got a decent risk tolerance, biotech stocks could be really attractive. I’ve used the Portfolio Grader to pick out several here that are worthy of further scrutiny. DRRX Durect $4.55 DVAX Dynavax Technologies $9.65 EDAP EDAP TMS $11.09 ELVN Enliven Therapeutics $22.68 FDMT 4D Molecular Therapeutics $17.04 FENC Fennec Pharmaceuticals $7.52 GERN Geron $2.22 Durect (DRRX) Source: shutterstock.com/Romix Image Durect (NASDAQ: DRRX ) is one of my favorite cheap stocks to buy right now.
The Top 7 Growth Stocks in Biotech 2023/03/03 23:57:06 InvestorPlace
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics. The rewards for bringing such products to market are significant. But biotech growth stocks also generally carry much higher risk than the average stock. Additionally, companies in the biotech industry face regulatory approval processes and intellectual property disputes that can result in significant near-term volatility. Nevertheless, the potential for substantial returns makes biotech stocks perpetually attractive. Identifying companies with the best chances of developing breakthrough drugs or therapies is paramount to success. Let’s take a look at seven companies that I think fit that profile. ITOS iTeos Therapeutics $17.30 VIR Vir Biotechnology $22.84 BEAM Beam Therapeutics $39.10 KNSA Kiniksa Pharmaceuticals $12.28 DVAX Dynavax Technologies $10.44 CMRX Chimerix $1.63 APVO Aptevo Therapeutics $2.15 iTeos Therapeutics (ITOS) Source: motorolka / Shutterstock.com Stocks like iTeos Therapeutics (NASDAQ: ITOS ) are the kind of equity biotech investors ought to be looking for.
Dynavax to Present at the Cowen 43rd Annual Health Care Conference 2023/03/01 21:15:00 Investors Dynavax
EMERYVILLE, Calif. , March 1, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Kelly MacDonald , Chief Financial Officer, will participate in a fireside chat